Comparative Effectiveness of endoscopic assessment of GER and BE
Comparative Effectiveness of endoscopic assessment of GER and BE
批准号:
8032920
负责人:
Prasad G. Iyer
金额:
$66.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2013-06-30
关键词:
Adverse eventAgeAreaArtsBarrett EsophagusBiopsyClinicalClinical effectivenessCommunitiesComplicationCountyDataDatabasesDetectionDiagnosticDirect CostsEarly DiagnosisEndoscopesEndoscopyEsophagealEsophageal AdenocarcinomaEsophageal injuryEsophagitisEvaluationFrequenciesGastroesophageal reflux diseaseGenderGeneral PopulationGoalsGrantHealth ExpendituresHealthcareHospitalsIncidenceInstitute of Medicine (U.S.)IntubationMalignant NeoplasmsMeasuresMedical centerMethodsMulticenter StudiesNoseOutcomePatient PreferencesPatientsPopulationProceduresQuestionnairesRandomizedRefluxReportingResearchResearch DesignResourcesRisk FactorsSamplingScreening procedureSedation procedureServicesSurveysSymptomsTechniquesTestingTherapeutic StudiesUnited StatesWorkabstractingbasecohortcomparative effectivenesscosteffectiveness researchimprovedinnovationinterestminimally invasivenovelnovel diagnosticspopulation basedprogramstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Barrett's esophagus (BE), a well-known complication of GER, is the strongest known precursor of esophageal adenocarcinoma (EAC). Thus, identifying effective screening approaches for the early detection of BE are highly desired. Current impediments to BE screening include 1) the inability to utilize sedated endoscopy (sEGD) effectively in populations and 2) current GER-based paradigms for detecting BE. Referral center studies demonstrate comparable accuracy between unsedated transnasal endoscopy (uTNE) and sEGD. However, patient acceptability and diagnostic yield with uTNE in general populations remain unknown. Preliminary Studies from our group have identified a significant level of interest for BE screening, and demonstrated initial feasibility of using uTNE and sEGD within a defined population. We propose to test the Central Hypothesis that the comparative effectiveness of uTNE will be greater than sEGD in population screening for BE with the following specific aims: Specific Aim 1: To assess participation in screening for BE with uTNE and sEGD in a population cohort. Subaim 1a: To compare participation rates for BE screening with uTNE and sEGD. We will randomly sample three age (> 50 years), gender and reflux symptom stratified cohorts (150 subjects each) from a defined population cohort. Each subject will be randomized to either sEGD (cohort 1), or uTNE in the hospital (huTNE, cohort 2), or uTNE within a mobile health care van (muTNE, cohort 3). Subaim 1b: To assess predictors of participation in population screening of BE. A priori demographic and clinical factors will be collected and analyzed to identify predictors of participation in screening. Specific Aim 2: To prospectively compare the clinical effectiveness of uTNE and sEGD in a population cohort. Subaim 2a: To compare the quality of esophageal assessment between sEGD, huTNE and muTNE cohorts. Quality criteria will include 1) successful esophageal intubation, 2) complete esophageal evaluation, 3) successful biopsy acquisition, 4) independent quality score by video evaluation using a validated scoring too. Subaim 2b: To compare the rates of detection of esophageal injury (esophagitis, strictures and BE) between cohorts stratified by presence/absence of GER symptoms using a validated symptom questionnaire. Specific Aim 3: To prospectively compare the short-term resource utilization and patient preferences for screening using sEGD, huTNE and muTNE in a population-based cohort. Subaim 3a: To measure the short term patient reported disutilities (patient preference associated with each test strategy) using a validated tool in the three test strategy cohorts. Subaim 3b: To compare the total short term costs (direct and indirect) and distribution of costs by type of service associated with each test strategy. The Significance that underlies the proposed research is based on the need to identify effective community- based screening strategies for BE which has the potential of improving outcomes of patients with EAC.
PUBLIC HEALTH RELEVANCE: Barrett's esophagus is a precursor and strong risk factor for esophageal adenocarcinoma: a cancer with rapidly rising incidence in the United States. In this proposal we aim to identify the most acceptable and accurate way to detect Barrett's esophagus in the community by comparing regular endoscopy (performed with sedation) to unsedated transnasal endoscopy (using a thin endoscope inserted through the nose) in the community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma
-
批准号:10439776
-
项目类别:
-
资助金额:$52.93万
-
财政年份:2019
-
负责人:Prasad G. Iyer
-
依托单位:
Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma
-
批准号:10204972
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Prasad G. Iyer
-
依托单位:
Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma
-
批准号:10657632
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2019
-
负责人:Prasad G. Iyer
-
依托单位:
PILOT PROJECTS, CROSS-BETRNET PROJECTS, & OTHER CROSS-BETRNET ACTIVITIES
-
批准号:10183182
-
项目类别:
-
资助金额:$15.43万
-
财政年份:2011
-
负责人:Prasad G. Iyer
-
依托单位:
Comparative Effectiveness of endoscopic assessment of GER and BE
-
批准号:8447834
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2010
-
负责人:Prasad G. Iyer
-
依托单位:
Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
-
批准号:7541547
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2008
-
负责人:Prasad G. Iyer
-
依托单位:
Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
-
批准号:7643809
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2008
-
负责人:Prasad G. Iyer
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: